- Home
- WALD vs NYXH Comparison
WALD vs NYXH Comparison
Compare WALD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | NYXH |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United Kingdom | Belgium |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.3M | 165.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WALD | NYXH |
|---|---|---|
| Price | $1.33 | $1.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.00 | ★ $9.33 |
| AVG Volume (30 Days) | 159.2K | ★ 240.8K |
| Earning Date | 03-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.89 | $213.98 |
| Revenue Next Year | $4.31 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.26 |
| 52 Week High | $3.22 | $6.87 |
Technical Indicators
Market Signals| Indicator | WALD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 45.43 |
| Support Level | $1.24 | $1.49 |
| Resistance Level | $1.83 | $1.70 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.24 | 8.82 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.